

DOCKET NO: 18438/09039

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of David R. Anderson et al.) Examiner: Unknown
Serial No: 10/729,139) Art Unit: Unknown
Filed: December 5, 2003	Deposit Account: 50-2548
Title: AMINOCYANOPYRIDINE INHIBITORS OF MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2	<i>)</i>)))

INFORMATION DISCLOSURE STATEMENT TRANSMITTAL LETTER

Mail Stop DD Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R 1.56, 1.97 and 1.98, Applicant is submitting the art shown on the attached list for consideration by the Examiner. By this submission, it is not admitted that any of the listed references are, in fact, prior art. The Examiner is respectfully requested to make an independent search and evaluation of all relevant prior art.

This Information Disclosure Statement is being filed prior to the mailing of a first office action on the merits and, therefore, no additional filing fee or certification is required.

The Examiner is encouraged to contact the undersigned at his convenience should there be any questions regarding this matter or require any additional information.

Respectfully requested,

NELSON MULLINS RILEY & SCARBOROUGH

<u>June 1, 2004</u> Date

Charles E. Dunlap

Registration No. 35,124

P.O. Box 11070

Columbia, SC 29211-1070 Phone: (864) 250-2238

Fax: (803) 256-7500

ereby certify that this paper, all attachments, and any fees are being deposited with the U.S. Postal Service as "First Class Mail" and is addressed: Mail Stop DD, Commissioner for Patents, P.O Box 1450, Alexandria, VA 22313-1450 on June 1, 2004

Terry P. Ballew
(Name and signature of person mailing paper or fee)

Practitioner's Docket No. 18438/09039

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

David R. Anderson, et al.

Application No.: 10/729,139

Group No.: Unknown

Filed: 12/5/2003

Examiner: Unknown

For: Aminocyanopyridine Inhibitors of Mitogen Activated Protein Kinase-Activated Protein

Kinase-2

Mail Stop DD **Commissioner for Patents** P. O. Box 1450 Alexandria, VA 22313-1450

CERTIFICATE OF MAILING UNDER 37 C.F.R. section 1.8(a)

I hereby certify that the attached correspondence comprising:

- 1. First Class Mail Certificate of Mailing for All (1 page)
- 2. Supplemental Information Disclosure Statement Transmittal Letter (2 pages)
- 3. Supplemental Information Disclosure Citation in an Application (2 pages)
- 4. References Enclosed (29 each)
- 5. Return postcard (1 page)

is being deposited with the United States Postal Service, with sufficient postage, as first class mail in an envelope addressed to:

> Mail Stop DD Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

On June 1, 2004.

Terry P. Ballew

Signature of person mailing paper

OTPE	1036
O HUL	200x B
PATENTS	For PTO-1

449

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number Optional 18438/09039	Application Number 10/729,139	
Applicant Anderson, et al.	Filing Date December 5, 2003	
Examiner	Group Art Unit	

11.5	PATEN	T DOC	UMENTS

EXAMINER INITIAL		DC	сим	ENT N	NUMB	ER		DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	6	4	3	2	9	6	2	08/13/02	Horneman	514	255.06	
	6	3	3	5	3	4	0	01/01/02	Gallagher et al.	514	252.05	
	6	2	6	8	1	6	3	07/31/01	Kongsbak et al	435	15	
	6	2	1	8	1	3	6	04/17/01	Kumar et al.	435	15	
	6	0	4	6	2	0	8	04/04/00	Adams et al	514	274	

FOREIGN PATENT DOCUMENTS

					Trar	nslation
 DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	YES	NO
WO 99/51735	14.10.99	Alexey Kotlyarov, et al.	C12N	15/11		Х
WO 01/29037 A2	26.04.01	Barry L. Johnson, et al.	C07D	471/00	Х	
WO 01/47892 A1	05.07.01	Dan M. Berger, et al.	C07D	215/54	Х	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

United States Patent Application Publication, Pub. No. US 2001/051620 A1, December 13, 2001
Article from Bioorganic & Medicinal Chemistry Letters, Vol. 5, No. 23, pp. 2783-2788, 1995 by C. W.
Smith et al., entitled The Anti-Rheumatic Potential of a Series of 2,4-Di-substituted-4H-Naphtho[1,2-
b]Pyran-3-Carbonitriles.

Abstract No. 132:260099 entitled "Anti-Inflammatory Substances" by N. Hirasawa et al.. Tanpakushitsu Kakusan Koso, 45(6): 1199-1203 (2000)

Abstract from J. Biol Chem., 2003 Jan., Vol. 278(3), pp. 1450-1456 by J.R. Burke et al. entitled BMS-34551 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice.

Abstract from The Journal of Biochemical Chemistry, 2002 Oct., Vol. 367(Pt 2): pp. 525-532 by A. Knebel, et al. entitled Stress-induced regulation of eukaryotic elongation factor 2 kinase by SB 203580-sensitive and -insensitive pathways.

Abstract from Biochim Biophys. Acts., 2002 July, Vol. 1598(1-2): pp. 88-97 by J.F. Schindler et al. entitled Examination of the kinetic mechanism of mitogen-activated protein kinase activated protein kinase-2.

Article from FEBS Letters 392 (1996), pp. 209-214 by A. Clifton et al. entitled A comparison of the substrate specificity of MAPKAP kinase-2 and MAPKAP kinase-3 and their activation by cytokines and cellular stress.

Article from FEBS Letters 364 (1995), pp. 229-233 by A. Cuenda et al. entitled SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1.

Article from The Journal of Immunology, 2000 July, 165: pp. 3951-3958, by A. K. De et al. entitled Exaggerated Human Monocyte IL-10 Concomitant to Minimal TNF-α Induction by Heat-Schock Protein 27 (Hsp27) Suggests Hsp27 is Primarily an Antiinflammatory Stimulus.

Article from The American Society for Biochemistry and Molecular Biology, Inc., 1995 Nov., Vol.:270(45), pp. 27213-27221 by K. Engel et al. entitled Constitutive Activation of Mitogen-activated Protein Kinase-activated Protein Kinase 2 by Mutation of Phosphorylation Sites and an A-helix Motif(*).

Article from The Journal of Biological Chemistry, 1997 Feb., Vol. 272(6); pp. 3296-3301 by I. N. Foltz et al. entitled Hemopoietic Growth Factors with the Exception of Interleukin-4 Activate the p38 Mitogen-activated Protein Kinase Pathway.

Article from Biochemical Journal, 1995 Sept., 311(Pt. 3); pp. 735-738 by G. W. Gould et al. entitled The activation of distinct mitogen-activated protein kinase cascades is required for the stimulation of 2-deoxyglucose uptake by interleukin-1 and insulin-like growth factor-1 in KB cells.

Form PTO-1	449	Docket Number Optional 18438/09039	Application Number 10/729,139				
INFO	RMATION DISCLOSURE CITATION	Applicant Anderson, et al.	Filing Date December 5, 2003				
(L	IN AN APPLICATION Ise several sheets if necessary)	Examiner	Group Art Unit				
		Unknown	Unknown				
	Article from The Journal of Immunol						
:	entitled Abnormal Migration Phenoty Kinase 2 ⁻¹ Neutrophils in Zigmond C	pe of Milogen-Activated Problems	Jein Kinase-Activated Protein				
	Gradients.	nambers containing romy	i Metrionyi-Ledcyi-i Henyialariine				
	Article from The Journal of Biologica	l Chemistry, 1999 May, Vol.	. 274(20): pp. 14434-14443 by O.				
	Heidenreich et al. entitled MAPKAP in Vivo*.	Kinase 2 Phosphorylates S	erum Response Factor in Vitro and				
	Article from The Journal of Biologica	I Chemistry, 2001 July, Vol.	276(45): pp. 41856-41861 by R.				
	Janknecht entitled Cell Type-specific		scription Factor ER81 by Mitogen-				
	activated Protein Kinase-activated P		050 060 h. A Katharan I.al				
	Article from Biochemical Society Tra entitled Is MK2 (mitogen-activated p						
	understanding post-transcriptional re						
	Article from Nature Cell Biology 1999						
	kinase 2 is essential for LPS-induced						
	Article from The Journal of Immunology	ogy, 2002 March, Vol. 168(9); pp. 4667-4673 by M. D. Lehner				
	al. entitled Mitogen-Activated Protein		Kinase 2-Deficient Mice Show				
	Increased Susceptibility to Listeria m						
	Article from Molecular Endocrinology	/, 2001, Vol. 15(5): pp. 716-	733 by E. T. Maizels et al. entitled				
ł	Developmental Regulation of Mitoge						
	(MAPKAPK-2/-3) in Vivo during Corpus Luteum Formation in the Rat.						
	Article from The Journal of Biochemical Chemistry, 1998 Sept., Vol. 273(38): pp. 24832-24838 by Miyazawa et al entitled Regulation of Interleukin-1β-induced Interleukia-6 Gene Expression in						
	Human Fibroblast-like Synoviocytes by p38 Mitogen-activated Protein Kinase.						
	Article from Circulation Research, 2000 Feb.: pp. 144-151 by N. Nakano et al. entitled Ischemic						
	Preconditioning Activates MAPKAPK2 in the Isolated Rabbit Heart.						
	Article from The Journal of Neurosci	ence, 1998 March, Vol. 18(5	5): pp. 1633-1641 by N. Bhat et al				
	entitled Extracellular Signal-Regulate						
	Kinases Regulate Inducible Nitric Ox Endotoxin-Stimulated Primary Glial (ecrosis Factor-α Gene Expression				
	Article from The Journal of Biologica		277(5): pp. 3065-3068 by A				
	Neininger et al. entitled MK2 Targets	AU-rich Elements and Red	ulates Biosynthesis of Tumor				
	Necrosis Factor and Interleukin-6 Inc						
	Article from The Journal of Biological Chemistry, 2000 April, Vol. 275(15): pp. 11284-11290 by E.						
	Paine et al. entitled Arachidonic Acid Activates Mitogen-activated Protein (MAP) Kinase-activated						
	Protein Kinase 2 and Mediates Adhesion of a Human Breast Carcinoma Cell Line to Collagen Type						
	IV through a p38 MAP Kinase-dependent Pathway. Article from Blood, 1999 Jan., Vol. 93(1): pp. 217-225 by M. P. Scheid et al. entitled Ceramide and						
	Cyclic Adenosine Monophosphate (c						
	Phosphorylation via Distinct Signalin						
	Survival.						
	Article from Proc. Natl. Acad. Sci, 2000 May, Vol. 97(10): pp. 5261-5266 by O. Werz et al. entitled 5						
	Lipoxygenase is phosphorylated by p38 kinase-dependent MAPKAP kinases.						
	Article from Kidney International, 200						
	Chronic exposure of human mesang	ial cells to high glucose env	ironments activates the p38 MAP				
CAMINER	pathway.	DATE CONSIDERED					
1		DATE CONSIDERED					
		-					